A Call For Better Monitoring and Treatment Of Scleroderma Patients PDF Print E-mail
Sunday, 01 July 2012 22:42
The New Zealand Scleroderma Group is calling for the introduction of a monitoring and treatment programme for New Zealanders with scleroderma to mark World Scleroderma Day on June 29.

Scleroderma is an autoimmune connective tissue disease that can affect many organs of the body. It is associated with excessive inflammation, fibrosis and vascular disease and causes hardening and restriction of the skin and internal organs such as the lungs and kidneys, sometimes progressing rapidly to death. It affects people of all ages.

It is likely that about 1,000 people in New Zealand have scleroderma with most of these patients being cared for by rheumatologists.

In 1994 the National Advisory Committee on Core Health and Disability Services considered that there should be one rheumatologist per 100,000 people. A 2004 study found that rather than improving, the provision of rheumatologists was worse with one rheumatologist per 251,211 people.

The study suggested inadequate funding and now the New Zealand Scleroderma Group calls on the Government to adequately fund rheumatological and other related services.

In 2007 a study of scleroderma patients at Middlemore Hospital in Auckland was published showing they were poorly monitored.

Although there is no cure for scleroderma, early detection and treatment of failing organs in scleroderma can improve quality and extend people’s lives.

There are monitoring programmes in centres around the world. In Australia 12 centres are involved in the Australian Scleroderma Screening Program. Three centres in New Zealand are members of a Europe based programme.

World Scleroderma Day marks the death of leading Swiss expressionist artist Paul Klee who died on this day in 1940 of scleroderma. He was diagnosed in 1935. Paul’s production slowed noticeably as scleroderma took hold. His artwork began to transform from light and joyful to murky and echoing.

The New Zealand Scleroderma Group is joining with other scleroderma groups around the world to raise awareness and improve health care for this potentially serious condition.

Source: Scoop Health (2012), "Scleroderma Patients: Call For Better Monitoring, Treatment"; Original article can be viewed here

 
More articles :

» Capillaroscopy, Autoantibody Findings Predict Raynaud's Progression

Abnormal findings on nailfold and the presence of scleroderma-specific autoantibodies in patients presenting with new-onset without overt connective tissue disease are powerful independent predictors of progression to definite .A landmark Canadian...

» Scleroderma and Lupus Health Study Claims No Environmental Link To Disease

The Massachusetts Department of Public Health (DPH) has released the results of an investigation into the occurrence of and lupus, two rare chronic diseases, in South Boston. The investigation found that the prevalence of scleroderma was indeed...

» The SCOT Study

SCOT is a clinical research study designed for people with severe forms of . SCOT stands for Scleroderma: Cyclophosphamide Or Transplantation. The SCOT study will compare the potential benefits of stem cell transplant and high-dose monthly...

» Survival In Pulmonary Hypertension

Stephen C. Mathai, Laura K. Hummers, Hunter C. Champion, Fredrick M. Wigley, Ari Zaiman, Paul M. Hassoun, and Reda E. GirgisARTHRITIS & RHEUMATISMVol. 60, No. 2, February 2009, pp 569–577 DOI 10.1002/art.24267 © 2009, American College of...

» Apoptosis Modulation as a Promising Target for Treatment of Systemic Sclerosis

St´ephane Chabaud and V´eronique J. MoulinReceived 1 June 2011; Revised 6 July 2011; Accepted 6 July 2011Systemic sclerosis (scleroderma, SSc) is a heterogeneous disease which develops into three forms: limited, intermediate, and diffuse. The...

» Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype?

Jo N. Fleming, Richard A. Nash, D. O. McLeod, David F. Fiorentino, Howard M. Shulman, M. Kari Connolly, Jerry A. Molitor, GretchenHenstorf, Robert Lafyatis, David K. Pritchard, Lawrence D. Adams, Daniel E. Furst, Stephen M....